/Viatris%20Inc%20logo%20on%20building-by%20SSKH-Pictures%20via%20Shutterstock.jpg)
With a market cap of $13.6 billion, Canonsburg, Pennsylvania-based Viatris Inc. (VTRS) offers a diverse range of pharmaceuticals, including branded, generic, and biosimilar products. It operates across various therapeutic areas and serves markets worldwide through four key segments: Developed Markets, Greater China, JANZ, and Emerging Markets. VTRS is expected to unveil its fiscal Q3 earnings results before the market opens on Thursday, Nov. 7.
Before the event, analysts anticipated the generic drugmaker to report a profit of $0.68 per share, down 12.8% from $0.78 per share in the same quarter last year. The company has surpassed Wall Street's earnings projections in two of the past four quarters while missing on two other occasions. VTRS exceeded the consensus estimate by a margin of 1.5% in the most recent quarter.
